Compare Mesoblast Limited (MESO) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Solaredge Technologies Inc — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while Solaredge Technologies Inc trades at $49.98 (market cap $2.96B). The key difference: Solaredge Technologies Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| MESO | SEDG | |
|---|---|---|
Market Cap | $2.17B | $2.96B |
Sector | Technology | Technology |
52-Week High | $20.96 | $78.51 |
52-Week Low | $12.88 | $24.42 |
Enterprise Value | $2.17B | $2.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SolarEdge Technologies (SEDG) trades at $48.65, down 9.01% in the last session, reflecting ongoing volatility. The stock shows a bearish technical signal with mixed earnings history—beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue declined to $1.18 billion in 2025, with a net loss of $405.45 million, though operating cash flow improved to $104.26 million. Analyst consensus is divided, with a hold-heavy rating and a $35.65 price target below the current price.
The outlook remains challenging due to persistent losses and competitive pressures, but potential catalysts include upcoming Q2 2026 earnings and demand for solar solutions. Key risks include high debt, margin pressures, and market sentiment shifts. Investors should weigh cost-cutting progress against sector headwinds for recovery potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
